ZhiShanWeiXin

Weekly News Amount
Total
${lastRankDetail.pages.length}
Financing ${lastRankDetail.financing_pages.length}
Product ${lastRankDetail.product_pages.length}
Negative ${lastRankDetail.sentiment_pages.length}
ZhiShanWeiXin is a biotechnology enterprise focusing on gene therapy and integrating gene drug research and development, technical service, technology transformation, large-scale production and sales. The future development of gene therapy drugs in ZhiShanWeiXin will focus on genetic diseases and neurodegenerative diseases

Signals

Events ${currentEventsPage.count} Events
Events (${currentEventsPage.count}) Date
Nothing Happens :-(
${e.desp} ${e.date}
News ${ rankDetail.pages.length } News Articles ${currentTimeRange.start} ~ ${currentTimeRange.end}
Article (${rankDetail.pages.length}) Tag
${article.en_title} ${article.tag}
Industry Financing Info

Research

Intelligence 0 Research Briefs

Competition

Competitors 5 Competitors
Company Industry Series Amount Announced Date

DingKeYiLiao

DingKeYiLiao is a high-tech company specializing in the research and development and production of vascular interventional medical treatment products, and has completed several registration tests and animal experiments of three types of products, among which DingKeYiLiao has the pre-market clinical trial of coronary drug balloon DCB ( Drug Coated Balloon ) Dissove TM with independent PCT intellectual property rights

Healthcare

series B

Nearly 100 million CNY

18/8/2020

EUCURE BIOPARMA

EUCURE BIOPARMA is an innovative antibody drug developer with a monoclonal antibody preparation platform, in vivo efficacy detection platform, in vitro antibody analysis platform and so on. It mainly provides products such as tumor immune antibody drugs, tumor immune checkpoint antibodies and so on for users, involving targeting tumor, immune anti - cancer, cardiovascular and other diseases

Healthcare

series B

120 million CNY

27/3/2018

Adagene

Adagene is committed to developing a new generation of biopharmaceutical companies with therapeutic and diagnostic antibody technology, using its own dynamic precision antibody technology ( DPL ) to develop new drugs leading the industry

Healthcare

series C

50 million USD

27/3/2018

LanssonPharm

LanssonPharm is a new drug research and development service provider, specializing in drug design, drug target identification, new drug structure design, pharmaceutical research, drug screening and evaluation and other fields, focusing on drug research and development of major diseases of the central nervous system, and carrying out drug informatics, new drug declaration, new drug policy consultation and other services

Healthcare

series A

Tens of millions CNY

28/1/2019

BociMed

BociMed is an enterprise engaged in drug research and development and clinical research. It provides high-quality research and development and outsourcing services including drug discovery, preclinical pharmaceutical research and development, clinical phase I-IV trials and registration declaration for enterprises through the establishment of a standardized service system

Healthcare

series B

Undisclosed

3/10/2020